We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has a third strike-out in a series of trials pitting its anti-inflammatory drug Ilaris (canakinumab) against nonmetastatic non-small cell lung cancer (NSCLC). Read More
Partners Daiichi Sankyo and AstraZeneca said a phase 3 trial of Enhertu (trastuzumab deruxtecan) to treat HER2-positive metastatic breast cancer met its primary and secondary endpoints, with the expected blockbuster drug showing a significant improvement in progression-free survival and overall survival. Read More
Brainstorm Cell Therapeutics is counting on a corrected subanalysis of a phase 3 trial to change the FDA’s mind about NurOwn, an unusual investigational treatment for amyotrophic lateral sclerosis (ALS). Read More
BeiGene’s anti-PD-1 monoclonal antibody tislelizumab has racked up more positive phase 3 numbers, proving itself just as good as sorafenib in extending the lives of patients with unresectable hepatocellular carcinoma. Read More
Abecma (idecabtagene vicleucel), a first-in-class CAR-T cell treatment codeveloped by Bristol Myers Squibb and 2seventybio, significantly improved progression-free survival relative to standard therapy in patients with relapsed multiple myeloma, the companies reported. Read More
Nebulized ensifentrine, an investigational inhaled anti-inflammatory, reduced exacerbations of chronic obstructive pulmonary disease (COPD) by 42 percent over 24 weeks — a significant benefit that could propel Verona Pharma to submit regulatory documents for a first-in-class treatment. Read More
Karuna Therapeutics’ investigational schizophrenia drug KarXT (xanomeline-trospium) reduced symptoms of the disorder in a late-stage study, with clinically meaningful changes seen within two weeks of beginning treatment. Read More
Data from an ongoing phase 3 study show the investigational PD-L1 antibody sugemalimab buys an extra four months of progression-free time for patients with unresectable stage III non-small cell lung cancer (NSCLC). Read More
Pfizer is scrapping its phase 3 trial of rare-disease cardiology candidate PF-07265803 and development of the drug, which the company inherited from Array Biopharma in its $11.4 billion acquisition of the company in 2019. Read More
Alnylam Pharmaceuticals announced that a year-long phase 3 trial of its drug patisiran showed that the therapy met both its major objectives in patients with transthyretin-mediated amyloidosis (ATTR) with cardiomyopathy, improving patients’ ability to walk and increasing their quality of life. Read More
The combination of Merck’s blockbuster anti-PD-1 therapy Keytruda and Eisai’s Lenvima failed to show superiority to the standard of care of Lenvima alone as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Read More